Tweets by IDWeek 2023

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Presentation Icons

Live Streamed

On Demand

325 Views

241. PK/PD Studies: Saturday, 12:15 - 1:30 p.m.

Poster Session: PK/PD Studies

(2563) Cytomegalovirus (CMV) Prophylaxis with Letermovir (LET) in Pediatric (Birth to < 18 years of age) Allogeneic Hematopoietic Cell Transplant (HCT) Recipients: Pharmacokinetics (PK), Safety and Efficacy Results of a Phase 2b study

Saturday, October 14, 2023

12:15 PM – 1:30 PM US ET

Location: Virtual

Presenting Author(s)

Johannes H. Schulte, MD

Pediatrician, Specialized physician for pediatric oncology and hematology
Charité Universitätsmedizin Berlin
Berlin, Berlin, Germany

AG

Aharon Gefen, MD, MSc

Ruth Rappaport Children’s Hospital
Haifa, Tel Aviv, Israel
Andreas H. Groll, MD

Professor of Paediatrics, Head of the Infectious Disease Research Programme and Deputy Director of the Department of Haematology/Oncology
University Children’s Hospital Muenster, Muenster, Germany
Muenster, Nordrhein-Westfalen, Germany
CF

Christopher J. Fraser, MD

Queensland Children’s Hospital
Brisbane, Queensland, Australia
VT

Valerie L. Teal, MS

Merck & Co., Inc.
Rahway, New Jersey, United States
BH

Barbara A. Haber, MD

Merck & Co., Inc.
Rahway, New Jersey, United States
CG

Christopher L. Gilbert, n/a

Merck & Co., Inc.
Rahway, New Jersey, United States
JM

Jacqueline B. McCrea, PharmD

Merck & Co., Inc.
Rahway, New Jersey, United States
MP

Mayankbhai Patel, PhD

Merck & Co., Inc.
Rahway, New Jersey, United States
KM

Karsten Menzel, PhD

Merck & Co., Inc.
Rahway, New Jersey, United States
CB

Cyrus Badshah, MD, PhD

Merck & Co., Inc.
Rahway, New Jersey, United States